Price$22.96+0.54 (+2.41%)
02:15 PM03:15 PM
News · 26 weeks43-57%
2025-12-142026-06-07
Mix1590d
- Insider6(40%)
- SEC Filings5(33%)
- Earnings4(27%)
Latest news
25 items- PRPrecipio to Present at the Planet MicroCap Las VegasNEW HAVEN, Conn., June 11, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces that it will be presenting at the Planet MicroCap Las Vegas 2026 on Wednesday, June 17, 2026, at 9:00 AM (Local Time, 12:00pm EST) at the Bellagio Resort & Hotel. Ilan Danieli, CEO and Zaki Sabet, COO of Precipio will be hosting the presentation and answering questions at the conclusion. "We're excited to participate in the Planet MicroCap conference and are looking forward to meeting with many of our existing, as well as new potential shareholders," said Ilan Danieli, CEO. "As a profitable company that is looking to raise awareness rather than raise capital, th
- INSIDERDirector Sandberg Richard A sold $22,517 worth of shares (900 units at $25.02) (SEC Form 4)4 - Precipio, Inc. (0001043961) (Issuer)
- INSIDERDirector Sandberg Richard A sold $77,784 worth of shares (3,134 units at $24.82), decreasing direct ownership by 20% to 8,142 units (SEC Form 4)4 - Precipio, Inc. (0001043961) (Issuer)
- PRPrecipio Announces Q1 2026 Financial ResultsNEW HAVEN, Conn., May 14, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces financial results for the first quarter ended March 31, 2026. Below are some of the key financial performance metrics for the Company. Please see the Company's Form 10-Q which was filed today for additional details. Revenue – $6.71M (vs. $6.69M in Q4-2025; $4.93M in Q1-2025). This was comprised of $6.05M in pathology revenue (up from $5.9M in Q4) and $0.66M in product revenue (down from $0.74M in Q4). The product revenue decline is temporary, and was largely driven by delayed shipment to one of the Company's largest product customers, shifting revenue recogn
- SECSEC Form 10-Q filed by Precipio Inc.10-Q - Precipio, Inc. (0001043961) (Filer)
- PRManagement team's 2025 market-based Options have vestedNEW HAVEN, Conn., May 13, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) announces that 2025 employee stock options granted to certain members of Precipio's management team vested last week because the Company's Common Stock price increased by more than 400% since the options were granted. As proposed by the Company's Compensation Committee in late 2024, rather than the standard 4-year time-based vesting period, management was offered and agreed to a market-based vesting structure whereby the options fully vest once the Company's share price exceeds a 10-day VWAP of $30.30. At the time of the grant, the share price and the options strike price w
- SECPrecipio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Precipio, Inc. (0001043961) (Filer)
- PRPrecipio Announces Q1-2026 Shareholder Update CallNEW HAVEN, Conn., May 06, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q1-2026 shareholder update call on May 18th, 2026, at 5:00 PM ET. The call will include remarks on the company's current core businesses, as well as a moderated live Q&A session at the end of the Company remarks. As part of Precipio's ongoing commitment to transparency and shareholder engagement, this call will be the first time the Company will incorporate a dedicated moderated live Q&A session into its quarterly update call. Management looks forward to addressing investor questions and providing additional insight into the Company's performance, strat
- SECSEC Form DEFA14A filed by Precipio Inc.DEFA14A - Precipio, Inc. (0001043961) (Filer)
- SECSEC Form DEF 14A filed by Precipio Inc.DEF 14A - Precipio, Inc. (0001043961) (Filer)
- INSIDERSEC Form 4 filed by Valauri Christina Rizopoulos4 - Precipio, Inc. (0001043961) (Issuer)
- INSIDERSEC Form 4 filed by Cossman Jeffrey4 - Precipio, Inc. (0001043961) (Issuer)
- INSIDERSEC Form 4 filed by Cohen David Seth4 - Precipio, Inc. (0001043961) (Issuer)
- INSIDERSEC Form 4 filed by Sabet Ahmed Zaki4 - Precipio, Inc. (0001043961) (Issuer)
- SECSEC Form 10-K filed by Precipio Inc.10-K - Precipio, Inc. (0001043961) (Filer)
- PRPrecipio Announces Q4 and year-end 2025 Shareholder Update CallNEW HAVEN, Conn., March 12, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q4 and year end 2025 corporate update call on April 2nd, 2026 at 5:00 PM ET. The call will include updates on all of the company's current core businesses. The conference call may be accessed by calling 646.307.1865. All callers should ask for the Precipio Inc. conference call. Listeners interested in submitting questions in advance should email their questions to investors@precipiodx.com and management will do its best to address those questions during the call. A replay of the call will be available approximately 24 hours after the call and may be
- PRPrecipio Announces Publication of a Joint Study with Memorial Sloan-Kettering Cancer Center Highlighting Its Cutting-Edge Bloodhound BCR::ABL1 AssayNEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) has announced the publication1 in the Journal of Clinical Pathology of a study conducted in collaboration with the Memorial Sloan-Kettering Cancer Center, demonstrating Precipio's new Bloodhound BCR::ABL1 assay for Chronic Myeloid Leukemia (CML). According to the publication's authors: "Its ease of use facilitates broad implementation and accessibility across clinical laboratories and resource settings." Ilan Danieli, CEO of Precipio, expanded on these findings. "Our Bloodhound BCR::ABL1 assay is the first and only assay that simultaneously detects and quantifies all fou
- SECPrecipio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Precipio, Inc. (0001043961) (Filer)
- PRPrecipio 2025 (Unaudited) Revenues Grew to $24.0M, a 30% Increase Year-Over-YearNEW HAVEN, Conn., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces some preliminary (unaudited) financials for Q4-2025 and for its fiscal year 2025. Below are some of the key financial performance metrics for the Company. Revenue Growth – Precipio's revenues increased from $18.5M in 2024 to $24.0M in 2025, an increase of 30% year over year. Q4-2025 revenues were $6.7M, an increase of 23% YoY from $5.4M in Q4-2024. Positive Adjusted EBITDA – Precipio will report Adjusted EBITDA of $0.95M for Q4-2025, and $1.23M for the full year 2025. This is compared to Adjusted EBITDA of $0.40M in Q4-2024 and ($1.5M) in full year 2024. Please
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Precipio Inc.SCHEDULE 13G/A - Precipio, Inc. (0001043961) (Subject)
- SECSEC Form S-8 filed by Precipio Inc.S-8 - Precipio, Inc. (0001043961) (Filer)
- NEWSDealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's EventATLANTIC CITY, NJ / ACCESS Newswire / January 23, 2026 / DealFlow Events today announced the growing list of companies scheduled to present and participate in one-on-one meetings with investors and analysts at the DealFlow Discovery Conference, taking place January 28-29, 2026, at the Borgata Hotel Casino & Spa in Atlantic City.More than 100 public and private companies are expected to participate in the conference, which brings together investors, analysts, growth company executives, and capital markets professionals for two days of company presentations, structured networking, and pre-scheduled 1:1 meetings.Below is the current list of companies confirmed to present and take meetings. Publ
- INSIDERAmendment: Director Andrews Ronald Asbury was granted 568 shares, increasing direct ownership by 4% to 15,796 units (SEC Form 4)4/A - Precipio, Inc. (0001043961) (Issuer)
- INSIDERAmendment: Director Cohen David Seth was granted 746 shares, increasing direct ownership by 1% to 53,688 units (SEC Form 4)4/A - Precipio, Inc. (0001043961) (Issuer)
- INSIDERAmendment: Director Cossman Jeffrey was granted 597 shares, increasing direct ownership by 4% to 15,340 units (SEC Form 4)4/A - Precipio, Inc. (0001043961) (Issuer)
PRPO FAQ
5 questionsWhat does Precipio Inc. do?
Precipio, Inc., a cancer diagnostics and reagent technology company, provides diagnostic products and services in the United States oncology market. Its product consists of clinical diagnostic services. The company's clinical diagnostic services focus on the diagnosis of different hematopoietic or blood-related cancers to oncologists. Its cytogenetics media IV-Cell enables laboratories to arrive at more accurate results; HemeScreen panel enables hospitals and laboratories to run an important genetic mutation test; and ICE-COLD-PCR enables detection of abnormalities in blood samples. The...Where does PRPO stock trade?
Precipio Inc. (PRPO) is listed on NASDAQ.What sector and industry is PRPO in?
Precipio Inc. operates in the Industrials sector, Biotechnology: Laboratory Analytical Instruments industry.What companies are similar to PRPO?
Notable peers in the same industry include A (Agilent Technologies Inc.), WAT (Waters Corporation), MTD (Mettler-Toledo International Inc.), PKI (PerkinElmer Inc.), RVTY (Revvity Inc.). Compare PRPO side-by-side with any of them on Quantisnow.How can I track PRPO on Quantisnow?
Quantisnow aggregates Precipio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PRPO to receive live email and push alerts on every new disclosure.